Under a tenth of patients who could benefit from GLP-1 drugs including Wegovy are able to get them, states the World Health Organization as it issues its first recommendations on the medications.
Given in excess of 1,000,000,000 individuals worldwide now classified as obese, it is urging increased and just access to GLP-1 medication.
According to estimates, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"Our new guidance recognises that excess weight is a chronic disease that can be treated with thorough and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are major barriers to universal availability to the injections that can aid individuals in losing substantial body mass, explains the agency.
Skinny Jab Scarcity
Despite the current most favorable case, the production of these medications would only suffice for about 100 million people – fewer than 10% of those who need them, according to the WHO.
The advice encourages governments and firms to widen availability, through strategies like licensing agreements.
Exclusive production rights on semaglutide – the main ingredient of the drug Wegovy – is due to expire in a number of nations in 2026.
The Way Obesity Drugs Work
GLP-1 drugs imitate a body's own hormone to reduce digestion speed, suppress the appetite and increase the sense of being full so people reduce food intake.
Individuals typically start to lose weight after several weeks of beginning the regular doses.
Evidence indicates people may regain a significant portion after a year of halting the drug, as their typical appetite come back.
To be above a healthy weight raises your risk for contracting diseases, including type 2 diabetes, heart disease, brain attack, and certain cancers.
Excess weight affects people in all nations and was associated with millions of fatalities worldwide in 2024, as per the health agency.
